Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, Irene Virgolini
Abstract
I]I-MIBG in rare NETs (such as paraganglioma, pheochromocytoma) and new non-SSTR-targeting radioligands are used in the personalization process of treatment. The present review will provide an overview of the current status of ongoing PRRT combination treatments.
Topics & Concepts
Radionuclide therapyMedicineNeuroendocrine tumorsOncologySomatostatin receptorInternal medicineClinical trialPeptide receptorTemozolomideOlaparibCancer researchPharmacologySomatostatinChemotherapyReceptorBiologyPoly ADP ribose polymeraseGenePolymeraseBiochemistryNeuroendocrine Tumor Research AdvancesNeuroblastoma Research and TreatmentsLung Cancer Research Studies